<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969578</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1206</org_study_id>
    <secondary_id>2013-000314-38</secondary_id>
    <nct_id>NCT01969578</nct_id>
  </id_info>
  <brief_title>Androgen Deprivation Therapy in Advanced Salivary Gland Cancer</brief_title>
  <official_title>A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached
      by multidisciplinary teams in high specialized centers. Until today no standard of care
      exists to treat these cancers. The identification of a target, the androgen receptor, in SG
      tumors has allowed for new treatment strategies options for this rare group of diseases. As a
      matter of fact, strong positivity for androgen expression has been found in salivary duct
      carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the
      efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients
      with recurrent and/or metastatic AR expressing SGCs.

      The study will include two cohorts of patients: Cohort A, which comprises chemo-naïve
      patients, and Cohort B, which comprises pretreated patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in Cohort A will be randomized 1:1 at the study entry to receive ADT (triptorelin +
      bicalutamide 50 mg) or standard chemotherapy. Patients of Cohort A randomized to the control
      arm (chemotherapy arm) will be given the option to enter Cohort B at the time of disease
      progression. As long as Cohort A is open to recruitment, patients who will be treated by
      chemotherapy will be simultaneously enrolled in Cohort B. Accrual in Cohort B will be stopped
      when recruitment of 76 eligible patients in Cohort A is reached.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>37 months after First Patient In</time_frame>
    <description>PFS is a primary outcome for cohort A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>37 months after First Patient In</time_frame>
    <description>RR is a primary outcome for cohort B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>37 months after First Patient In</time_frame>
    <description>RR is a secondary outcome for cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>37 months after First Patient In</time_frame>
    <description>PFS is a secondary outcome for cohort B</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>37 months after First Patient In</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events according to CTCAE v4.0</measure>
    <time_frame>37 months after First Patient In</time_frame>
    <description>adverse events will be recorded using International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, the investigator will assess whether those events are drug related (reasonable possibility, no reasonable possibility) and this assessment will be recorded in the database for all adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Salivary Gland Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel
Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Androgen Deprivation Therapy (ADT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT = bicalutamide + triptorelin
Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide + triptorelin</intervention_name>
    <arm_group_label>Androgen Deprivation Therapy (ADT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin + Doxorubicin</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin + Paclitaxel</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of recurrent and/or metastatic salivary duct cancer;
             adenocarcinoma, NOS; and AR expression in at least 70% of nuclei of neoplastic cells
             based on central review

          -  Sufficient tissue must be available either historically or a biopsy must be done as a
             part of this study and sent to central review for patients enrolled in both cohorts

          -  Presence of at least one uni-dimensional measurable lesion by CT-scan or MRI according
             to RECIST criteria version 1.1 (target lesion).

          -  Patients older than 18 years old;

          -  Performance Status ECOG 0-1;

          -  Adequate bone marrow function:

          -  WBC ≥ 3.5/10exp9L

          -  absolute neutrophil count ≥ 1,5x10exp9/L

          -  hemoglobin &gt; 9 g/dL

          -  platelet count ≥ 100x10exp9/L

          -  Adequate liver function:

          -  AST &lt; 2.5 times upper limit of normal

          -  ALT &lt; 2.5 times upper limit of normal

          -  bilirubin &lt; 1.5 times upper limit of normal

          -  the concomitant evidence of AST &lt; 2.5 times upper limit of normal, ALT &lt; 2.5 times
             upper limit of normal and bilirubin &gt; 1.5 times upper limit of normal is not allowed

          -  Adequate renal function:

          -  serum creatinine level (≤ 1.3 mg/dL)

          -  calculated creatinine clearance ≥ 60 mL/min based on the standard Cockcroft and Gault
             formula

          -  Adequate cardiac function as demonstrated by a clinically normal 12 lead ECG;
             additionally for patients who will receive Cisplatin and Doxorubicin adequate cardiac
             function should be demonstrated by a left ventricular ejection fraction (LVEF) ≥ 50%
             (within 2 weeks prior to treatment start)

        Exclusion Criteria:

          -  Actively bleeding tumor if the patient is intended to be treated with carboplatin

          -  Patients with bone disease or brain disease as the sole disease site; brain metastases
             are allowed in case of systemic disease, but must have been treated at least 4 weeks
             before enrollment and must be stable after that;

          -  recent history of congestive heart failure, unstable angina within the past 3 months,
             cardiac arrhythmia, myocardial infarction, congenital long QTc prolongation, stroke,
             TIA within the past 6 months;

          -  previous cardiac toxicity induced by another anthracycline or previous exposure to
             maximum cumulative dose of another anthracycline if the patient is intended to be
             treated with doxorubicin

          -  history of allergic reactions attributed to compounds of similar chemical or
             biological composition to cis/carboplatin, paclitaxel, doxorubicin, bicalutamide or
             triptorelin;

          -  concomitant medications with terfenadine, astemizole, cisaprid

          -  use of phenytoin

          -  Patients who received vaccine for yellow fever

          -  active second malignancy during the last five years except non melanomatous skin
             cancer or carcinoma in situ of the cervix;

          -  positive serum pregnancy test within 1 week prior to the first dose of study treatment
             for Women of child bearing potential (WOCBP);

          -  no adequate birth control measures, as defined by the investigator, during the study
             treatment period and for at least 6 months after the last study treatment for patients
             of childbearing / reproductive potential.

          -  psychological, familiar, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule; those conditions should be
             discussed with the patient before registration in the trial;

          -  written informed consent not given according to ICH/GCP, and national/local
             regulations, before patient registration

          -  participation in another interventional clinical trial in the preceding 4 weeks prior
             to randomization

          -  for cohort A patients: previous chemotherapy for recurrent/metastatic disease
             (previous chemotherapy given concomitantly with RT in the past is allowed, including
             cisplatin but it should be completed at least 6 months before enrollment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Licitra</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale Tumori</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Harrington</last_name>
    <role>Study Chair</role>
    <affiliation>The Royal Marsden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominiek Staelens, PhD</last_name>
    <email>dominiek.staelens@eortc.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>General study e-mail address</last_name>
    <email>1206@eortc.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Vienna - General Hospital AKH</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thorsten Fuereder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk Schrijvers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yassine Lalami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Pascal Machiels</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pol Specenier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Clement</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence Digue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier Cupissol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frederic Rolland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Malard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joel Guigay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Paris - Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bertrand Baujat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole - Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Pierre Delord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Christine Kaminsky-Forrett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline Even</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sebastian Ochsenreither</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena-Radiation Therapy and Radiooncology Clinic</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Orlando Guntinas-Lichius</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Dietz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Athens University - Attikon University General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amanda Psyrri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute Of Oncology</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erika Hitre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cecilia Moro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laura Locati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Provinciale per i Servizi Sanitari - Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessia Caldara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis - Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Buter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sjoukje Oosting-Lenstra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carla van Herpen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salivary duct cancer</keyword>
  <keyword>adenocarcinoma, NOS</keyword>
  <keyword>androgen deprivation</keyword>
  <keyword>androgen receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

